PRINCETON, N.J. / Feb 01, 2024 / Business Wire / UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in February:
Guggenheim 6th Annual Biotechnology Conference – February 7-8, 2024
Fireside Chat: February 8, 2024 at 11:00 AM ET
Format: 1x1 meetings
Location: New York, NY
Webcast Link
Oppenheimer 34th Annual Healthcare Life Sciences Conference – February 13-14, 2024
Presentation: February 13, 2024 at 12:00 PM ET
Format: Virtual
Webcast Link
A webcast from both conferences will also be available via the Investors section of UroGen’s website, www.urogen.com. A replay of the webcast will be available for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.
| Last Trade: | US$10.51 |
| Daily Change: | -0.25 -2.32 |
| Daily Volume: | 12,805 |
| Market Cap: | US$443.520M |
November 06, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
